Syngene International Limited – Auditor Appointment

Date of Announcement: 29 April 2026

Key Highlights

• New Statutory Auditor: M/s. S. R. Batliboi & Associates LLP
• Effective Date: 29 July 2026
• Term: 60 months (5 years)
• Board Approval: 29 April 2026, 10:00 – 16:10 hrs
• Compliance: Auditor holds a valid peer‑review certificate from ICAI.

Strategic Implications

• Governance: Strengthens compliance framework and aligns with best‑practice audit standards.
• Operational Impact: No direct effect on day‑to‑day business, R&D pipelines, or commercial activities.
• Financial Reporting: Anticipated continuity in audit quality; any material audit observations will be disclosed per SEBI regulations.

Risks & Opportunities

• Risks: Minimal; primarily limited to potential audit adjustments if the new auditor identifies accounting issues.
• Opportunities: Enhanced audit credibility may improve investor confidence and could positively influence credit ratings.

Outlook

The auditor change is a neutral‑to‑positive development, reinforcing corporate governance without altering the company’s growth trajectory. Investors can expect continued focus on Syngene’s core biotech and pharmaceutical services while maintaining regulatory compliance.

Prepared for investors on 29 April 2026.